FIG. 1



A
mAb 5J7 (DENV-3)
FRNT50 [Ab] ug/ml
1
0.1
0.01
0.001
*
rDENV-1
rDENV-3
rDENV-1/3
B
mAb 1F4 (DENV-1)
1
0.1
0.01
0.001
*
rDENV1
rDENV3
r-DENV1/3

FIG. 2A




Donor 019 (Primary DENV-1)
Donor 006 (primary DENV-1)
Donor 106 (Primary DENV-1)
fold dilution
10000
1000
100
10
1
rDENV-1
rDENV-3
rDENV-1/3
virus

FIG. 2B


Donor 118 (Primary DENV-3)
Donor 125 (Primary DENV-3)
Donor 033 (primary DENV-3)
fold dilution
10000
1000
100
10
rDENV-1
rDENV-3
rDENV-1/3
Virus
virus



28 days post infection (DPI)
60 DPI
90 DPI
120 DPI
180 DPI
FRNT50
10000
1000
100
10
1
DENV-1
DENV-2
DENV-3
DENV-4

FIG. 3

FIG. 4A




DENV3-1F4 vs 1F4 (DV1 mAb)
2.0
1.5
1.0
0.5
0.0
OD 405
icWestPac'74
3001ic
3001-1F4E
3001-1F4R
3001-1F4S
0.000
0.000
0.001
0.010
0.100
1.000
10.000
mAb 1F4 [ug/mL]

FIG. 4B


DENV3-1F4 vs 5J7 (DV3 mAb)
1.0
0.8
0.6
0.4
0.2
0.0
OD 405
0.000
0.000
0.001
0.010
0.100
1.000
10.000
mAb 5J7 [ug/mL]



Human Sera 010 (DV 1)
Human Sera 106 (DV 1)
Human Sera 006 (DV 1)
Human Sera 024 (DV 1)
Fold dilution
10000
1000
100
10
1
DV1
DV3
DV3-1F4E

FIG. 5A

FIG. 5B




Human Sera 125 (DV 3)
Fold dilution
10000
1000
100
10
1
DV1
DV3
DV3-1F4E
Human Sera 133 (DV 3)
Fold dilution
10000
1000
100
10
1
DV1
DV3
DV3-1F4E
Human Sera 118 (DV 3)
Fold dilution
10000
1000
100
10
1
DV1
DV3
DV3-1F4E
Human Sera 105 (DV 3)
Fold dilution
10000
1000
100
10
1
DV1
DV3
DV3-1F4E

FIG. 6


28 day 3001-1F4E
10000
1000
100
10
FRNT50
DENV-1
DENV-2
DENV-3
DENV-4
serotype